Prosecution Insights
Last updated: November 04, 2026

Purdue Pharma L.P.

Technology area: Biotechnology & Pharmaceuticals

6 pending office actions • 5 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days

Analysis

Purdue Pharma L.P. has 6 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 6 distinct examiners and 5 distinct art units, showing separate examiner assignments with some concentration among technical groups.

BAGNAL, CINDY LILIANA is the busiest examiner, with 1 pending matter. Because the examiner count matches the action count, counsel cannot rely on repeated examiner treatment to guide responses. The lower art-unit count supports reviewing at least one group for shared technical or procedural patterns.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

6
Total Pending OAs
2
Non-Final OAs
3
Final Rejections
1
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

0
Overdue
1
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
5
Medium (83%)
1
Easy (17%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only4 (67%)
§112 only1 (17%)
Double-patenting + other1 (17%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

6
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

60 h
Manual time on pending OAs
12 h
Time saved (low, 20%)
21 h
Time saved (mid, 35%)
0.5 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
BAGNAL, CINDY LILIANA 1 — —
TCHERKASSKAYA, OLGA V 1 55.5% +46.4%
KENYON, JOHN S 1 79.8% +18.1%
YOUNG, MICAH PAUL 1 55.1% +30.0%
WAX, ROBERT A 1 25.7% +3.9%
COPPINS, JANET L 1 72.6% +26.1%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
17918012 COMPOSITIONS AND METHODS FOR EMERGENCY RESCUE WAX, ROBERT A —

Interview Candidates (4)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.

App #TitleExaminerDue in
17910199 COMPOSITIONS AND METHODS FOR NALOXONE DELIVERY YOUNG, MICAH PAUL 6d
18746814 PHARMACEUTICAL DOSAGE FORMS TCHERKASSKAYA, OLGA V —
18389356 COMPOSITIONS AND METHODS FOR OPIOID ANTAGONIST DELIVERY KENYON, JOHN S —
17059761 COMPOSITIONS AND METHODS FOR OPIOID OVERDOSE RESCUE COPPINS, JANET L —

Top Art Units

Art UnitApps
1615 2
1621 1
1625 1
1618 1
1628 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18878591 METHODS OF TREATING OR PREVENTING OVERACTIVE BLADDER SYNDROME BAGNAL, CINDY LILIANA 1621 §103 Non-Final OA — Pending Dec 23, 2024
18746814 PHARMACEUTICAL DOSAGE FORMS TCHERKASSKAYA, OLGA V 1615 §112Other Final Rejection — Pending Jun 18, 2024
18389356 COMPOSITIONS AND METHODS FOR OPIOID ANTAGONIST DELIVERY KENYON, JOHN S 1625 §102DP Non-Final OA — Pending Nov 14, 2023
17910199 COMPOSITIONS AND METHODS FOR NALOXONE DELIVERY YOUNG, MICAH PAUL 1618 §103 Final Rejection 6d Pending Feb 22, 2023
17918012 COMPOSITIONS AND METHODS FOR EMERGENCY RESCUE WAX, ROBERT A 1615 §103 Non-Final OA — Pending Oct 10, 2022
17059761 COMPOSITIONS AND METHODS FOR OPIOID OVERDOSE RESCUE COPPINS, JANET L 1628 §103 Final Rejection — Pending Nov 30, 2020

Managing Purdue Pharma L.P.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Purdue Pharma L.P. have?

Purdue Pharma L.P. has 6 pending office actions as of November 2026, spread across 5 art units and 6 examiners.

Which USPTO examiner handles the most Purdue Pharma L.P. applications?

Cindy Liliana Bagnal has the most, with 1 of Purdue Pharma L.P.'s pending office actions.

What technology area are Purdue Pharma L.P.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month